We conclude that the promotion of M1 macrophages represents an opportunity to enhance the anti-glioma effect achieved by anti-CD47 monoclonal antibodies, which also promote the classical (M1) phenotype of macrophages. This evidence concerns the gene CD47 and central nervous system cancer.